Illustration of vitamin D binding protein molecules interacting with lung alveoli.

Vitamin D Binding Protein: Unlocking Its Role in Lung Health

Lena Kashyap monogram
Lena Kashyap in Health & Wellness October 2026 • 4 min read.

"A deep dive into how genetic variations in vitamin D binding protein may influence chronic obstructive pulmonary disease (COPD)."


Chronic Obstructive Pulmonary Disease (COPD) is a significant global health concern, ranking as the third leading cause of mortality worldwide. Characterized by persistent airflow limitation, COPD is primarily linked to tobacco smoking, but emerging research highlights the involvement of genetic factors in its development.

Among these genetic influences, vitamin D binding protein (DBP) has garnered attention. DBP, a glycosylated protein mainly produced in the liver, plays a crucial role in vitamin D transport and immune modulation. This article delves into the intricate relationship between DBP gene polymorphisms, serum DBP levels, and COPD risk, shedding light on potential therapeutic avenues.

Recent studies have explored how variations in the DBP gene might influence COPD susceptibility. By examining the rs7041 and rs4588 polymorphisms and measuring DBP protein levels in COPD and non-COPD subjects, researchers aim to uncover how these genetic differences impact lung function and disease progression.

AI Search Multiple angles on this topic

COPD Associations and Research Gaps

Earlier studies reported associations between vitamin D3 [25(OH)D], vitamin D-binding protein (VDBP), and COPD. A 2015 PLOS study set out to investigate these associations in relation to longitudinal outcomes. A 2013 study also noted associations with COPD and FEV1, while reporting limited data on emphysema; the supplied summaries do not give a numerical estimate of population impact.

DBP and the Macrophage Hypothesis

A study described genetic polymorphisms in vitamin D-binding protein (DBP) as having been associated with COPD. It proposed that DBP may be present in the airway and contribute to lung disease through its indirect role in macrophage activation. The airway mechanism was presented as a hypothesis.

How Do DBP Gene Variations Affect Lung Function in COPD?

Illustration of vitamin D binding protein molecules interacting with lung alveoli.

A study compared Thai males with COPD to non-COPD subjects, focusing on two key DBP gene polymorphisms: rs7041 and rs4588. The research revealed that individuals with the GC1-1 genotype showed an increase in forced expiratory volume at 1 second (FEV1), a critical measure of lung function. While this increase was noted, it did not reach statistical significance, indicating the need for further investigation.

Interestingly, the study observed significantly lower average DBP serum levels in COPD subjects compared to their non-COPD counterparts. This suggests that reduced DBP levels may be associated with COPD. Further analysis showed a positive correlation between serum DBP and FEV1 in non-COPD subjects, reinforcing the importance of DBP in maintaining lung function.

  • rs7041 and rs4588 Polymorphisms: Focus on understanding specific genetic variations within the DBP gene.
  • FEV1 Measurement: Understanding that FEV1 is a key indicator of lung function.
  • GC1-1 Genotype: Note that GC1-1 is a specific genetic variant being studied.
  • Serum DBP Levels: Acknowledge that DBP levels are measured in the blood.
AI Search Multiple angles on this topic

Reviews Examine Vitamin D in COPD

A review published April 4, 2026, synthesizes evidence on vitamin D’s pathophysiological role in COPD. It highlights potential adjunctive use to reduce exacerbations and improve lung function, while emphasizing gaps in mechanistic and translational understanding. These are review aims and potential applications, not a claim that those benefits have been established.

Smoking as a Potential Confounder

A source on vitamin D-binding protein variants and COPD cautions that smoking may have confounded previous studies. It notes smoking is the major risk factor for COPD. This raises a limitation in interpreting earlier associations between DBP variants and COPD, rather than disproving those associations.

Sputum VDBP by Genotype and COPD Group

In a prospective study of smokers with COPD, only the GC1S/1S genotype among those studied showed different sputum VDBP levels between groups. Levels were 112.1 [103.4–123.2] ng/mL in COPD stage I and 355.5 [110.2–973.5.0] ng/mL in COPD stage II+, compared with 38.0 [14.9–92.3] ng/mL in healthy non-smokers. The reported comparisons had p = 0.034 and p = 0.002, respectively.

The findings suggest that DBP variations might contribute to COPD risk through both inflammatory and vitamin D circulation processes. Genetic factors, differing across regions and ethnicities, could play a significant role in how DBP influences COPD development. Therefore, understanding these relationships could pave the way for targeted interventions.

Implications and Future Directions

The research indicates that variations in DBP may be a risk factor for COPD, influencing lung function through inflammation and vitamin D metabolism. Further studies are needed to fully elucidate these mechanisms and explore potential therapeutic strategies. Understanding the genetic and environmental factors affecting DBP levels could lead to personalized approaches in managing and preventing COPD.

AI Search Multiple angles on this topic

GC Variants and Population Differences

Different allelic arrangements of GC produce variants with differing isoelectric points and vitamin D3-binding efficiency. The review notes that, across populations, rs4588 and rs7041 may tag different sets of regulatory and structural SNPs in GC haplotypes. These differences may affect GC protein expression and function.

The Vitamin D Evidence Gap

A May 2026 source describes a “vitamin D paradox” in pulmonary medicine: observational studies link low vitamin D with worse outcomes in COPD, asthma, and cystic fibrosis. It also reports that randomized controlled trials of oral supplementation have consistently failed to show clinically meaningful benefit. The source frames this contrast as a gap between observational associations and trial outcomes.

What Vitamin D-Binding Protein Does

VDBP was first described by Hirschfeld in 1959 as a marker in human serum gamma-globulin and characterized as a group-specific component. In 1975, it was identified as the plasma protein that binds vitamin D. Its major role is transporting 25-hydroxyvitamin D, the major circulating form, and 1,25-dihydroxyvitamin D, the most active vitamin D metabolite.

What the lung-function difference represents

  • 0.427 LIn a combined analysis of controls and people with COPD, the 1S-1S genotype was associated with FEV1 that was 0.427 L higher than in people with other genotypes; the comparison was statistically significant.[1]

In a separate smoker cohort, higher sputum VDBP was associated with lower predicted FEV1 at baseline and follow-up for the GC1/1S genotype, but not with lung-function change over the follow-up period. This distinguishes an association with lung-function level from evidence of subsequent decline.[2]

  • If Gc2’s protective association is not explained by a genotype difference in neutrophil chemotaxis, what other biological pathway accounts for it?[3]
25-hydroxyvitamin D
The major circulating form of vitamin D transported by VDBP.[1]
G-actin
Extracellular actin that VDBP can help clear as a scavenger protein.[4]
C5a-mediated neutrophil chemotaxis
Neutrophil movement that can be enhanced by Gc-globulin through complement C5a.[3]

Sources

  1. Relationship of Vitamin D Binding Protein Polymorphisms and Lung Function in Korean Chronic Obstructive Pulmonary Disease (pmc.ncbi.nlm.nih.gov)
  2. Sputum Vitamin D Binding Protein (VDBP) GC1S/1S Genotype Predicts Airway Obstruction: A Prospective Study in Smokers with COPD (pmc.ncbi.nlm.nih.gov)
  3. Vitamin D binding protein variants and the risk of COPD. (pubmed.ncbi.nlm.nih.gov)
  4. The vitamin D axis in the lung: a key role for vitamin D-binding protein. (pubmed.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What exactly is Vitamin D Binding Protein (DBP), and why is it important in the context of lung health?

Vitamin D Binding Protein (DBP) is a glycosylated protein primarily produced in the liver. Its main function is to transport vitamin D in the body. DBP also plays a role in immune modulation. Understanding DBP's function is vital because it connects genetic factors to lung health, particularly in the context of Chronic Obstructive Pulmonary Disease (COPD). Variations in the DBP gene can influence how efficiently vitamin D is circulated and how the immune system responds, potentially affecting COPD susceptibility.

2

What are the rs7041 and rs4588 polymorphisms, and why are they significant in the study of Chronic Obstructive Pulmonary Disease (COPD)?

The rs7041 and rs4588 polymorphisms are specific genetic variations within the Vitamin D Binding Protein (DBP) gene. These polymorphisms are important because they can influence an individual's susceptibility to Chronic Obstructive Pulmonary Disease (COPD). Researchers analyze these variations to understand how genetic differences impact lung function and disease progression. Identifying these genetic markers can potentially lead to personalized therapeutic strategies for managing and preventing COPD.

3

What does FEV1 measure, and why is it important when studying Chronic Obstructive Pulmonary Disease (COPD)?

FEV1, or Forced Expiratory Volume in 1 second, is a critical measure of lung function. It indicates the amount of air a person can forcefully exhale in one second. In the context of Chronic Obstructive Pulmonary Disease (COPD), FEV1 is used to assess the severity of airflow limitation, a hallmark of the disease. Monitoring FEV1 helps healthcare providers evaluate disease progression and the effectiveness of treatments. Its correlation with Vitamin D Binding Protein (DBP) levels suggests a link between genetic factors and lung performance.

4

What is the GC1-1 genotype, and what does it tell us about lung function?

GC1-1 is a specific genotype, a genetic variant, of the Vitamin D Binding Protein (DBP) gene. Studies have shown that individuals with the GC1-1 genotype might exhibit an increase in FEV1, a measure of lung function. This genotype is important because it highlights how specific genetic makeups can influence lung health in Chronic Obstructive Pulmonary Disease (COPD). While the increase in FEV1 may not always be statistically significant, it points to the complex interplay between genetics and lung function.

5

What are serum DBP levels, and what do they indicate regarding Chronic Obstructive Pulmonary Disease (COPD)?

Serum DBP levels refer to the concentration of Vitamin D Binding Protein (DBP) measured in the blood. Lower average DBP serum levels have been observed in Chronic Obstructive Pulmonary Disease (COPD) subjects compared to non-COPD subjects, suggesting a potential association between reduced DBP levels and COPD. The correlation between serum DBP and FEV1, especially in non-COPD subjects, reinforces the importance of DBP in maintaining lung function. Monitoring serum DBP levels could be a valuable tool in assessing COPD risk and progression.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.